Replies to post #521388 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

No it isn’t.

Yes, it is. Unless you think the company has been lying for years and years in PR's, SEC filing and (peer-reviewed) publications?

Your definition of personalized is not correct.

What do you think my definition of that is?

Plus melanoma has very few antigens.

Melanoma is one of the most highly mutated malignancies which is why the response rates to therapies, like TIL and checkpoint blockade is high.

There is no need for “personalization”.

Well, they think differently.

It has some level of “customization” but they have preselected the antigens and it is very likely the “customization” is not customized at all.

They start with tissue samples (tumour and blood), undertake next gen sequencing of tumour to normal DNA and RNA, before using a proprietary bioinformatics algorithm to predict and select neoantigens.

It is artificial and it is really no skin off their back to offer all 20 antigens, or not.

They encode up to 34 neoantigens.